Similar results were obtained for CLL patients, for whom the highest sensitivity was observed for: CD8+TLR2+, CD19+TLR2+, TLR4, and TLR9 expression for all lymphocyte subpopulations tested (Supplementary Materials—Table S1). This evidence concerns the gene TLR4 and B-cell chronic lymphocytic leukemia.